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Mechanical Thrombectomy and Functional
Outcomes After Stroke
To the Editor The 2015 American Heart Association/American
Stroke Association focused update for the earlymanagement
of acute ischemic stroke recommended endovascular ther-
apy as an adjunctive therapy to intravenous thrombolysis.1
Dr Badhiwala and colleagues2 performed a meta-analysis re-
gardingendovascular thrombectomyforacute ischemic stroke
and found that endovascular thrombectomy was associated
with improved functionaloutcomes (odds ratio [OR], 1.56 [95%
CI, 1.14-2.13]; P = .005) and no significant difference in all-
causemortality (OR,0.87 [95%CI,0.68-1.12];P = .27)at90days
compared with standard medical care. The authors included
the SYNTHESIS (Intra-arterial vs Systemic Thrombolysis for
Acute IschemicStroke)expansion trial,3which randomizedpa-
tients with acute ischemic stroke to receive endovascular
therapy alone (without intravenous tissue plasminogen acti-
vator [tPA])vs tPA.Wearguethat theSYNTHESISstudy3should
havebeenexcluded fromtheanalysis because it is fundamen-
tally different from the other included studies. Including
SYNTHESIS in the Badhiwala et al analysis could have under-
estimated the effect of interventional treatment on impor-
tant outcomes.
A similar meta-analysis evaluating the efficacy of endo-
vascular thrombectomy in acute ischemic stroke excluded
the SYNTHESIS expansion trial and also included 2 recently
presented studies (ie, THERAPY [Randomized, Concurrent
Controlled Trial to Assess the Penumbra System’s Safety and
Effectiveness in the Treatment of Acute Stroke] and
THRACE [Trial and Cost Effectiveness Evaluation of Intra-
arterial Thrombectomy in Acute Ischemic Stroke]).4 This
analysis demonstrated improvement in functional out-
comes (risk ratio [RR], 1.45 [95% CI, 1.22-1.72]; P < .001)
with endovascular thrombectomy. Thus, thrombectomy for
acute stroke appears to be beneficial. However, accurate
treatment summary estimates depend on correct selection
of trials for analysis.
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To the Editor Dr Badhiwala and colleagues1 followed the
Cochrane Collaboration standards to conduct a systematic
review on the use of mechanical thrombectomy in acute
ischemic stroke. Reviewing 8 randomized clinical trials, the
authors concluded that, in selected patients, endovascular
thrombectomy was associated with improved functional
outcomes over standard medical care, without differences
in adverse events.
All included studies used a prospective randomized
open blinded end point (PROBE) design2 rather than an
investigator-participant-evaluator blind design, and 5 stud-
ies were stopped early, 4 for benefit. The Cochrane Collabo-
ration tool for assessing risk of bias and the Grades of Rec-
ommendation, Assessment, Development and Evaluation
(GRADE) approach,3-5 both used by the authors, state that a
“low risk of bias” should not be endorsed when selection,
performance, or other forms of bias are present. The PROBE
design assumes reliable randomization to allocate partici-
pants to treatment groups but does not include blinding of
patients or study personnel.2 More importantly, evidence
suggests that trials stopped early for benefit often overesti-
mate treatment effects.4
We believe that studies without allocation concealment
or blinding of participants and personnel and with other
sources of bias cannot accurately be rated as high quality, as
Badhiwala and colleagues did. Selection, performance and
other biases would warrant a downgrading of the risk of bias
item. If the quality rating fell by 1 level for each downgraded
factor,5 this could change the quality of evidence from a
moderate-to-high level to a moderate level, implying that
further research is still needed. This reduction may have an
important effect on the level of confidence in the estimate
of effect4,5 and consequently in the way different stakehold-
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ers (clinicians, patients, and policy makers) perceive the
health effect of a given therapeutic intervention.
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In Reply Dr Elgendy and colleagues suggest that the
SYNTHESIS1 trial should have been excluded from our meta-
analysis because the endovascular therapy group did not
receive intravenous tPA. At the time SYNTHESIS1 and the
Interventional Management of Stroke III (IMS III)2 were
designed, there was limited data on combining intravenous
tPA with endovascular thrombectomy.3 The rationale for
combination therapy was the yet unproven assumption that
endovascular thrombectomy and intravenous tPA could work
in synergy; however, there was also concern about a possible
higher risk of hemorrhagic transformation, especially at full
doses of tPA. Reflecting these opposing hypotheses, the
SYNTHESIS1 trial aimed to evaluate direct endovascular
intervention, whereas IMS III2 sought to test the safety and
efficacy of endovascular therapy after intravenous throm-
bolysis. With the state of the available literature, we thought
it would be most informative to perform an overall pooled
analysis of endovascular thrombectomy (with or without
intravenous tPA) vs standard medical care, and subsequent
analyses stratified by concurrent use of intravenous tPA with
mechanical thrombectomy. We found more favorable func-
tional outcomes when thrombectomy was combined with
intravenous tPA than when performed in isolation. This has
important implications on a systems level, as it lends support
to “drip-and-ship” (tPA intravenous drip and shipping
patients to the angiogram catheter suite for endovascular
thrombectomy) paradigms of care. Moreover, Elgendy and
colleagues allude to the THERAPY and THRACE trials. Both
studies have yet to be published, and only intermediary
results from THRACE are available. The inclusion of incom-
plete data from these trials, yet selective exclusion of
SYNTHESIS,1 could bias their meta-analysis.4
Dr Rodrigues and colleagues suggest that the rating of the
quality of evidence in our meta-analysis should be changed
from moderate to high to moderate because all trials used a
PROBE design and because 4 trials were stopped early for
benefit. However, it would not have been feasible to blind
participants and clinicians, given that the intervention
requires an operative procedure whereas the control therapy
does not. The use of a sham procedure would pose an ethical
conundrum. Furthermore, the lack of blinding is unlikely to
have biased treatment effect estimates, considering that out-
come assessors were blinded, there was no evidence to sug-
gest cointervention or differential behavior by clinicians, and
objective outcomes were used (eg, modified Rankin Scale
[mRS] score, revascularization, mortality, intracerebral hem-
orrhage), which are less susceptible to bias by the placebo
effect.5 Similarly, although trials stopped early for benefit
may overestimate the treatment effect, this is mostly an issue
when event numbers are small.6 The primary outcome in the
trials stopped early, except 1, was the mRS score. This out-
come was examined using the proportional odds ratio (shift
analysis), which takes into account the sum distribution of all
mRS scores. This outcome, being derived from large event
numbers, is less prone to overestimation. The factors Rodri-
gues and colleagues point out can introduce bias into any
trial, but they do not in themselves indicate or ensure bias. A
more careful look reveals that these characteristics are
unlikely to have contributed significant bias to the results in
this specific setting. We maintain that the quality of the evi-
dence is moderate to high.
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Conflict or Confluence of Interest?
To theEditorArecentViewpoint1 suggested that “the term con-
flict of interest is pejorative” and proposed using “confluence
of interest” instead, along with visually mapping the com-
plex system of biases within and around research. Themate-
rial is thought-provoking but problematic.
To us it is far from clear that conflict of interest is a depre-
ciative term.Although therearebiasing factorsother thancon-
flictsof interest,2 thephrase captures thedifficultnatureof the
topic and is not pejorativewhencorrectlyused to speakof per-
ceived or potential—not actual—conflicts. Furthermore, con-
fluenceof interest is itself aproblematic term. It implies that in-
terests flow together, whereas reality suggests that some
interests cancounteract oroutweighothers. Theauthors seem
tobelieve that “implying an alignment of primary and second-
ary interests” for which biasing factors are not seen as prob-
lematic would be preferable to admitting that potential con-
flictsexist,buttheydidnotofferanyargumentsfor thisposition.
Theobjectivemightbe tominimizebiasing factors, but renam-
ingthetermusedtorefer tobiaseswhile theobjective is far from
beingmet could undermine all the work done toward encour-
aging researchers todeclarepotential conflicts.3,4 To takeadif-
ferent example, if there was a problem with the terminology
“fabrication of results,” would it be renamed “full and trans-
parent reporting” simply because the latter is the ultimate aim
incombating the former?Thiswouldnotseemappropriate, and
the same applies to conflict of interest.
Moreover, although details of the terrain-mapping
approach and its usefulness remain unclear, it is surprising
that the authors think placing a 3-dimensional terrain map-
ping of fame and fortune resembling a heat map on consent
forms would be a “simple and accessible” approach. Con-
sent forms are already overlong and overcomplicated with-
out giving potential study participants visual representa-
tions of how fame and fortune may bias investigators,
institutions, funders, and journals in the complex interplay5
of research.
Ultimately, renamingconflictsof interest“confluenceof in-
terest”woulddomoreharmthangoodandtheproposedterrain
mappingmay complicate the issue beyond reasonable limits.
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In Reply Dr Shaw and colleagues think that the term “conflict
of interest” is not pejorative because the implication is that
this infers the potential for conflict rather than its reality. We
do not think so. A conflict is a clash, a quarrel, a squabble, or
a disagreement, often of a protracted nature, not just the
prospect of its occurrence. Journals require increasingly “full
and transparent reporting,” for example, by provision of
metadata, but do not request authors to address a priori their
“fabrication of results” unless they detect evidence that this
has occurred.
Weagree that thepresent consent forms“arealreadyover-
long and overcomplicated,” yet they focus on fiscal forms of
bias to which the investigator is potentially liable and do not
address the diversity of relevant stakeholders and the lure of
fame, perhaps even more distracting to many academic in-
vestigators than money alone. There has been considerable
progress in the visualization of complex data in the genomic
era. This approach can readily be harvested to display for pa-
tients, scientists, and regulators potential sources of bias that
are pertinent to a body of work. It seems to us that some ef-
fort along these lines is long overdue; itwould be an improve-
ment on the current copious, wordy, and often impenetrable
consent forms—apicture, after all, isworth a thousandwords.
Everyone has biases. Rather than present these pejora-
tively, as a clash of values that undermines validity, it seems
more constructive tomine the complexityof thesebiases, pre-
sent them in an accessible fashion, and seek to determine
whether they are confluentwith the interests of patients, sci-
entists, and regulators whomight base their decisions on the
results of a given piece of work.
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